Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Yield10 Bioscience, Inc. (YTENQ)
:YTENQ
Holding YTENQ?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -81.48%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in regulatory approvals and strategic partnerships for omega-3 products, contrasted by challenges related to cash flow, continuing net losses, and the shift away from biofuels due to market uncertainties.Company Guidance
During Yield10 Bioscience's Q4 2023 earnings call, the guidance focused on commercializing omega-3 products derived from Camelina seed oil. The company outlined its strategy to deliver omega-3 product samples and file for regulatory approval in Chile in 2024, targeting aquafeed, pet food, and other markets. Revenue projections estimate a potential of $150 million to $300 million from scaling production to 150,000 to 300,000 acres over the next five years. Yield10 also anticipates generating significant licensing revenue from its Camelina technologies, with a focus on R&D services to third parties for biofuel applications. Financially, the company ended 2023 with $1.1 million in cash, reporting a net loss of $14.5 million for the year, and expects its cash to support operations into Q2 2024, with ongoing efforts to secure additional funding.USDA-APHIS and US EPA Approvals
Yield10 Bioscience received USDA-APHIS regulatory approval for growing HT Camelina and expects U.S. EPA approval for adding Camelina to its commercial herbicide label soon, enabling large-scale planting.
Omega-3 Product Milestones
Yield10 achieved regulatory approval for growth of omega-3 Camelina traits ahead of schedule and plans to commercialize omega-3 products by 2025-2026, aiming for $150 million to $300 million in revenue from 150,000 to 300,000 acres.
Strategic Partnerships and Licensing
Yield10 signed its first license agreement with Vision Bioenergy Oilseeds, majority-owned by Shell Oil, to scale up HT Camelina production and provide R&D services, securing $3 million in payments.
Camelina Oil Value Chain Establishment
Successfully demonstrated closed-loop production of Camelina oil, contracting over 1,200 acres of winter Camelina, and engaged growers for spring Camelina planting.
---
YTENQ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
YTENQ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $0.54 | $0.40 | -25.93% |
| Aug 14, 2024 | $1.54 | $1.50 | -2.60% |
| May 15, 2024 | $2.88 | $2.37 | -17.71% |
| Apr 01, 2024 | $9.19 | $5.28 | -42.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Yield10 Bioscience, Inc. (YTENQ) report earnings?
Yield10 Bioscience, Inc. (YTENQ) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Yield10 Bioscience, Inc. (YTENQ) earnings time?
Yield10 Bioscience, Inc. (YTENQ) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is YTENQ EPS forecast?
Currently, no data Available
---